A novel combination of the 4-1BB/CD137 agonist utomilumab with the PD-1 blocking mAb pembrolizumab was well tolerated and demonstrated antitumor activity in patients with advanced malignancies. Most responses were durable and observed across a broad range of tumors, including small-cell lung cancer, non-small-cell lung cancer, anaplastic thyroid carcinoma, renal cell carcinoma, and squamous cell carcinoma of the head and neck, warranting further evaluation. 
Introduction
Preliminary results from a phase I study (NCT01307267) of single-agent utomilumab in patients with advanced solid malignancies and in combination with the anti-CD20 mAb rituximab in patients with relapsed or refractory CD20 + non-Hodgkin lymphoma showed that treatment was well tolerated (up to an utomilumab dose of 10 mg/kg), with no doselimiting toxicities (DLTs), and provided preliminary evidence of clinical activity in these patient populations (9, 10) .
Induction of T-cell activation and cytokine production (e. 
Methods

Study design, objectives, and treatment
The primary objective of this phase Ib open-label, multicenter, dose-escalation study was to estimate the maximum tolerated dose (MTD) and select the recommended phase II dose (RP2D) for the combination of utomilumab plus pembrolizumab administered every 3 weeks (Q3W) to patients with advanced solid tumors. The primary endpoint was DLT occurring in the first 2 treatment cycles (6 weeks). Secondary endpoints included the overall safety and tolerability profile, PK parameters of both mAbs, anti-drug antibody (ADA) levels, and objective tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Further, exploratory endpoints included changes in peripheral blood biomarkers (e.g., percentage of activated T-cell subsets and IFN-γ levels).
Research. Patients received utomilumab in combination with pembrolizumab 2 mg/kg (30-minute intravenous infusion) on the first day of each 21-day cycle. The starting dose for utomilumab was 0.45 mg/kg (1-hour intravenous infusion) with escalation to 0.9 mg/kg, 1.8 mg/kg, 3.6 mg/kg, and 5 mg/kg in the subsequent cohorts. In the event of excessive toxicity at the starting dose, de-escalation to a dose of 0.2 mg/kg (dose -1) was predefined for the subsequent cohort. Intra-patient dose escalation was not permitted.
The MTD was defined as the highest combination dose with a DLT rate <25% based on the novel time-to-event continual reassessment method (TITE-CRM) design with cyclical adaptive weight function (18, 19) , which is a Bayesian model-based design that allows continuous evaluation of toxicity based on complete and incomplete data on DLT using a time-to-event method. Dose escalation would be halted if the maximum sample size of 45 patients was reached, or after treatment of 9 evaluable patients at the estimated MTD, or if all doses demonstrated excess toxicity and the MTD could not be determined.
A maximum of 32 treatment cycles were planned for the study. Treatment was to be continued until disease progression, patient withdrawal, unacceptable toxicity, or premature study termination. Clinically stable patients could continue receiving study treatment post progression until disease progression was confirmed ≥4 weeks later or if they had signed an addendum consent to continue with study drug and at repeat imaging they had no further progression and were still deriving clinical benefit in the opinion of the treating investigator. Early treatment discontinuation could be considered for patients who had achieved a confirmed complete response (CR), if they had 
Patients
Patients (aged ≥18 years) were included in the study if they had a histological or cytological diagnosis of advanced/metastatic solid tumor malignancy that had progressed on standard therapy or for which no standard therapy was available; had measurable disease by RECIST v1.1, Eastern Cooperative Oncology Group (ECOG) 0-1, and adequate renal, cardiac, hepatic, and bone marrow function. Patients were excluded if they had a primary central nervous system malignancy or known symptomatic, unstable, progressing brain metastases; were unable to discontinue clinically therapeutic doses of systemic steroid therapy (not inhaled or topical) or any other form of immunosuppressive therapy within 14 days prior to registration; had received chemotherapy, growth factors, investigational agents, or major surgery within 28 days, a live vaccine within 30 days, or mAb therapy within 60 days before registration. Prior treatment with anti-PD1/PD-L1 or other immunostimulatory mAbs was allowed. Patients were also excluded if they had an active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic steroids or immunosuppressive agents, had a history of toxicities associated with prior immunotherapy, had had a severe hypersensitivity reaction to treatment with another mAb, or were known to be positive for ADA to utomilumab or pembrolizumab. The following adverse events were considered DLTs if they occurred during the observation period (first 2 cycles/6 weeks) of dose escalation and were attributable to 1 or both study drugs: hematologic adverse events (febrile neutropenia, grade 4 neutropenia, grade 3 neutropenic infection, grade 3 thrombocytopenia with bleeding, or grade 4 thrombocytopenia), non-hematologic adverse events (grade ≥3 toxicities including maximally treated grade ≥3 nausea, vomiting, or diarrhea; grade 4 increased aspartate aminotransferase or alanine aminotransferase), grade ≥3 non-hematologic laboratory abnormality requiring medical treatment or hospitalization, or inability to complete 2 infusions of utomilumab and pembrolizumab in the DLT-observation period.
Tumor response
Tumor assessments were performed radiographically by computed tomography or magnetic resonance imaging at baseline, 9 weeks after the first dose of study treatment, every 6 weeks thereafter, whenever disease progression was suspected (e.g., symptomatic deterioration), and at the end of treatment/withdrawal (if not done in the previous 6 weeks), using RECIST v1.1. For patients with a confirmed CR or partial response (PR), tumor assessments could be performed as clinically indicated.
Pharmacokinetics
Blood samples were collected for PK analyses of utomilumab on day 1 (predose and end of infusion) of cycles 1-4; day 1 (predose, end of infusion, 2, 6, and 24 hours post start of infusion), day 8, and day 15 of cycle 5; day 1 of cycle 6 (predose); day 1 (predose, end of infusion, 24 hours) and day 8 of cycle 7; then predose every 2 cycles up to cycle 12; every 4 cycles thereafter; and at end of treatment (EOT). Blood samples were collected for PK analyses of pembrolizumab on day 1 of cycles 1-5 (predose and end of infusion); on day 1 (predose, end of infusion, 24 hours) and day 8 of cycle 7; predose every 2 cycles up to cycle 12; every 4 cycles thereafter; at the EOT; and at 28 days, 3 and 6 months after EOT.
Samples were analyzed for utomilumab and pembrolizumab concentrations using validated analytical methods. Standard serum PK parameters including maximum observed serum concentration (C max ), time to maximum serum concentration (t max ), and area under the concentration-time curve (AUC) were estimated for utomilumab using non-compartmental analysis.
Immunogenicity
Blood samples for utomilumab and pembrolizumab immunogenicity testing were collected predose in cycles 1, 3, 5, 7 and, subsequently, predose every 2 cycles up to 
Statistical analyses
The TITE-CRM design was implemented in this study as described with cyclical adaptive weight function (18, 19) . A dose-escalation steering committee was established to facilitate the trial conduct process (20) . To achieve a reliable MTD estimate, the sample size for the dose-escalation cohorts was set at up to 45 patients with early stopping rules. The objective response rate per RECIST 1.1 was summarized with exact 2-sided 95% CI calculated using the Clopper-Pearson method. PK parameters were summarized with descriptive statistics. For biomarker endpoints, the mean and standard deviation, median, and minimum/maximum levels of biomarker measures (e.g., percentage of CD3 + T cells) were determined at baseline and after treatment, with calculation of the percentage change from baseline.
Results
Patients
Twenty-three patients received pembrolizumab 2 mg/kg and utomilumab 0.45 mg/kg (n = 5), 0.9 mg/kg (n = 3), 1.8 mg/kg (n = 3), 3.6 mg/kg (n = 3), or 5.0 mg/kg (n = 9) (Supplementary Table S1 ). All patients were assessed for safety and tumor response. The number of study treatment cycles received by patients across all dose levels ranged from 2 to 28, with a median duration of treatment of 19.4 (range, 6.0-86.9) weeks. The majority (n = 14, 61%) of patients discontinued treatment due to disease progression or relapse. Two (8.7%) patients discontinued due to non treatmentrelated adverse events; 1 (4.3%) patient was lost to follow-up; 2 (8.7%) patients
Research. Table 1 ). The majority of patients had received prior systemic therapy (91.3%, 1-9 lines of treatment) with a median of 3 prior regimens. One patient each had received prior treatment with pembrolizumab, nivolumab, or ipilimumab; none of the patients had received prior combined treatment with nivolumab and ipilimumab.
Dose-limiting toxicities and safety
As no DLTs were observed in any of the 23 DLT-evaluable patients across all dose groups (0.45-5.0 mg/kg), dose escalation continued until the highest planned dose level and the MTD was estimated, per the TITE-CRM design, to be at least 5.0 mg/kg Q3W of utomilumab when combined with pembrolizumab 2.0 mg/kg Q3W. The combination was well tolerated with mild toxicities, as shown in Table 2 .
The most common treatment-related adverse events included fatigue (34.8%), rash (34.8%), pruritus (21.7%), and pyrexia, decreased appetite, dry mouth, dry skin, and nausea (each 13%); all were grades 1-2. Treatment-related grade 3-4 adverse events included grade 3 adrenal insufficiency (n = 1; 3.6 mg/kg) and grade 3 hypokalemia (n = 1; 5 mg/kg). No grade 5 treatment-related adverse events were observed in this study.
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The most frequent, treatment-emergent (all causality, all grades) adverse events observed in this study were fatigue (43.5%), rash (43.5%), cough (34.8%), decreased appetite (30.4%), and nausea (30.4%) ( Table 2 ). Of these, only fatigue was reported as a grade 3-4 adverse event, in 1 patient. Other grade 3-4 adverse events observed in >2 patients included anemia and hyponatremia (each n = 3, 13%). Seven deaths were reported in this study, all due to disease under study, 5 of which occurred within 90 days after last treatment dose (1 of these 5 deaths occurred within 30 days after last dose of treatment).
Antitumor activity
Six of the 23 treated patients achieved a confirmed complete (CR) or partial response (PR) (objective response rate 26%; 95% CI, 10.2-48.4%) ( Table 3) . Two Best overall response of stable disease (defined as ≥1 stable disease assessment, or better, ≥6 weeks after first dose of study treatment and before progression, not qualifying for CR or PR) was achieved by 10 (43.5%) patients across tumor types. Five of these 10 patients had stable disease lasting >4 months. Seven (30.4%) patients had best overall response of disease progression.
Pharmacokinetic and anti-drug antibodies analysis
A summary of PK parameters of utomilumab following multiple dosing in combination with pembrolizumab is presented in Supplementary Table S2 . Mean C max appeared to increase with increasing doses of utomilumab, from 7.63 g/mL at 0.45 mg/kg to 92.6 g/mL at 5 mg/kg. Dose-dependent increases were also observed for utomilumab mean area under the concentration-time curves over the dosing interval (AUC tau ), from 1,093 gh/mL at 0.45 mg/kg to 10,480 gh/mL at 5 mg/kg. The exposure of utomilumab administered in combination with pembrolizumab was comparable to that observed with utomilumab alone (9) . Mean concentration-time profiles for pembrolizumab are presented in Supplementary Fig. S2 . The exposure for 
Pharmacodynamic analyses
Cytokine analyses were performed to assess potential relationships between cytokine induction and adverse events due to the combination. shown). Patients with a clinical response showed a trend toward higher levels of IFN-γ compared with non-responders at 6 and 24 hours post-dose on cycle 5 day 1 (Fig. 3A) . 
Discussion
In the current immunotherapy landscape, responses to single-agent PD-1 checkpoint inhibitors range from 10% to 30% across a number of solid malignancies, including melanoma, NSCLC, RCC, SCCHN, and others (1) (2) (3) (4) (5) (6) (7) 21) . However, the majority of patients do not respond upfront or eventually progress. Combination immunotherapies with agents such as CTLA-4 inhibitors may enhance efficacy and responses, but also substantially increase toxicity, as reported in patients with melanoma or lung cancer (22, 23) . Despite the successes of PD-1 checkpoint blockade across various malignancies, there is still an urgent need to improve outcomes and survival for patients with advanced solid tumors.
We report results from the first study designed to evaluate safety, clinical activity, PK, and pharmacodynamics of a novel combination of the 4-1BB/CD137 agonist utomilumab with the anti-PD-1 mAb pembrolizumab for the treatment of patients with advanced solid malignancies. This combination was notable for its safety profile and tolerability at the doses evaluated in this study, and the encouraging antitumor activity.
Based on the lack of DLTs observed in the dose-escalation groups (utomilumab 0.45-5.0 mg/kg), the MTD was estimated to be at least 5 mg/kg Q3W for utomilumab when combined with pembrolizumab 2 mg/kg Q3W. No treatment-emergent adverse events of clinical relevance were reported. The only combination treatment-related grade 3-4 adverse events observed in this study were grade 3 adrenal insufficiency (previously reported in rare cases with pembrolizumab therapy [24] ) and grade 3 hypokalemia (1 patient each). None of the patients discontinued treatment due to a treatment-related adverse event, and the duration of treatment ranged from 2 to 28 cycles with a median of 6 cycles. The frequency of ADA (~70%) observed in this study was comparable to that previously reported for single-agent utomilumab (9) . The general lack of significant treatment-associated adverse events indicates that the development of ADA did not result in safety-related consequences for ADA-positive patients. The safety profile of the combination appeared consistent with historical data for pembrolizumab alone (4-7), although further studies will be required to clearly establish the safety and tolerability of this combination. very unfavorable prognosis and no effective therapeutic options available to patients (25) (26) (27) (28) (29) . Although rare, anaplastic thyroid cancer is a biologically aggressive tumor. The provocative findings, in this study, of pulmonary and skin metastases that responded rapidly to treatment should strongly encourage further development of this combination in this largely untreatable malignancy (28, 29) .
It was striking to observe the depth and durability of the antitumor activity observed in the patients who responded to therapy (median duration of response not reached; 95% CI, 5.1 months-NE). However, due to the low number of patients and the exploratory nature of the dose-finding part of this trial, no efficacy conclusions can be drawn for this combination. Furthermore, because pembrolizumab is active as a single agent across multiple malignancies (4-7), the contribution of utomilumab to the observed antitumor activity cannot be determined in this trial, in the absence of a concurrent randomized control arm. Preliminary results from a prior study had shown a confirmed CR (Merkel cell carcinoma), two confirmed PRs (melanoma and Merkel cell carcinoma), and stable disease as best overall response in 6/27 (22%) patients with advanced solid malignancies treated with single-agent utomilumab (9) . No drug interactions were observed between utomilumab and pembrolizumab. This is consistent with the concept that both biologics are eliminated via a nonspecific catabolic degradation process, which is unlikely to alter their clearance upon coadministration. Research.
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